SCHEMBL16463547

SCHEMBL16463547

Cc1ccc(CNC2CCNCC2)cc1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SOS1 Q07889 2/20 0.39
HRH3 Q9Y5N1 1/20 0.38
EP300 Q09472 1/20 0.38
HTR6 P50406 1/20 0.38
ALDH1A1 P00352 1/20 0.38
KDM1A O60341 2/20 0.37
MAOA P21397 1/20 0.37
MAOB P27338 1/20 0.37
CARM1 Q86X55 1/20 0.37
PRMT6 Q96LA8 1/20 0.37
PRMT5 O14744 1/20 0.37
WDR77 Q9BQA1 1/20 0.37
ACHE P22303 1/20 0.36
BACE1 P56817 1/20 0.36
MEN1 O00255 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36
POLB P06746 1/20 0.36
CCNT1 O60563 1/20 0.36
DPP7 Q9UHL4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3633900 0.86 KDM1A (0.48) SOS1HRH3HTR6KDM1AMAOB
SCHEMBL16250572 0.82 HRH3 (0.38) SOS1HRH3KDM1AMAOBPRMT5
SCHEMBL12448915 0.82 PRMT5 (0.49) SOS1HRH3ALDH1A1PRMT5WDR77
SCHEMBL16462862 0.82 EPHX2 (0.40) HRH3EP300ALDH1A1CARM1PRMT6
SCHEMBL3633946 0.80 ALDH1A1 (0.39) SOS1HRH3EP300ALDH1A1KDM1A
SCHEMBL16465131 0.79 KDM1A (0.43) HRH3EP300ALDH1A1KDM1A
SCHEMBL17140254 0.79 SLC6A2 (0.38) SOS1HRH3EP300ALDH1A1KDM1A
SCHEMBL16463802 0.79 CARM1 (0.41) EP300ALDH1A1CARM1PRMT6ACHE
SCHEMBL16464766 0.78 ALDH1A1 (0.40) HRH3EP300ALDH1A1PRMT5WDR77
SCHEMBL3355681 0.78 BCHE (0.54) HRH3KDM1AMAOAMAOBACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2906216-B1 INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS KUMAR AJAY (GB) 2020-06-24 EP disclosed
US-9643979-B2 Inhibitors of DNA gyrase for the treatment of bacterial infections VITAS PHARMA RESEARCH PRIVATE LIMITED (IN) 2017-05-09 US disclosed
US-20150284408-A1 INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS KUMAR, AJAY, DR. (GB) 2015-10-08 US disclosed
EP-2906216-A2 INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS Vitas Pharma Research Private Limited (IN) 2015-08-19 EP disclosed
WO-2014057415-A2 INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS VITAS PHARMA RESEARCH PVT LTD (IN) 2014-04-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150284408-A1 INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS TOP1, TOP2A, DNASE1 SOS1 3093/4885HRH3 2263/4885EP300 1526/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.